A weight loss drug developer's stock soars after a $198 million IPO
Inflatie
In This Story BIOA Shares of BioAge Labs ( BIOA ), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public offering (IPO) price on Thursday. Suggested Reading 'Inane': Southwest Airlines CEO calls out the activist investor that's trying to kick him out Trump's plans would increase inflation and unemployment while tanking GDP, report says Ozempic could even help prevent opioid overdoses, study says The top 15 cities for startups Share Share this Video Facebook
din zilele anterioare